ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements
Novelix Pharmaceuticals reported no deviation in its July 2026 fund raise utilisation for the September quarter. This periodic statement records no new business event.
Novelix Pharmaceuticals Ltd reported revenue from operations of ₹44.7 Cr (+22.8% YoY) and net profit of ₹1.6 Cr (+220.0% YoY) for Q2 FY27.
Novelix Pharmaceuticals has given prior intimation of a board meeting on 11 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window stays closed until forty-eight hours after the meeting.
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Novelix Pharmaceuticals held its 32nd Annual General Meeting on 30th September, 2026, transacting ordinary and special business items via e-voting and video conferencing.
Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.
Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.
Novelix Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026. The company has fixed September 23, 2026, as the cut-off date for e-voting.
Novelix Pharmaceuticals Limited appointed Mr. Gnana Prakash Gattu as Whole-time Director for a five-year term. The appointment, effective August 29, 2026, awaits shareholder approval.
Novelix Pharmaceuticals Ltd approved the AGM notice and appointed Mr. Gnana Prakash Gattu as a Whole-time Director in its board meeting outcome.
Novelix Pharmaceuticals Limited will hold a board meeting on August 29, 2026, to discuss the AGM notice, annual report, and a director appointment.
Novelix Pharmaceuticals executed a five-year land lease for micro algae cultivation in Telangana. The company will pay a monthly rent of Rs. 5,000 for 0.925 acres.
Novelix Pharmaceuticals filed its Statement of Deviation and Variation for the quarter ended June 30, 2026, reporting no deviations in fund utilization.
Novelix Pharmaceuticals Ltd reported revenue from operations of ₹36.9 Cr (+64.7% YoY) and net profit of ₹1.2 Cr (+1100.0% YoY) for Q1 FY27.
Novelix Pharmaceuticals has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026.
Novelix Pharmaceuticals promoters acquired 3,37,500 shares worth Rs. 6.75 Crore via warrant conversion. The acquisition increases the promoter group's consolidated equity stake in the company.
Novelix Pharmaceuticals allotted 25,00,000 equity shares to promoter group entities following warrant conversion. This increased the promoter group stake from 36.42% to 39.35%.
Novelix Pharma approved a total equity raise of ₹74.34 Crore through a promoter warrant conversion and a non‑promoter preferential issue. The issue adds 4.5 million shares to its paid‑up capital.
Novelix Pharmaceuticals allotted 45,75,000 equity shares, raising approximately Rs. 11.90 Crore. This includes warrant conversions for promoters and a preferential issue to 16 non-promoter investors.
Novelix Pharmaceuticals held an Extra Ordinary General Meeting on July 1, 2026. The meeting included a special resolution for issuing equity shares on preferential basis.
Novelix Pharmaceuticals convened an EGM for July 1, 2026, to approve a ₹6.84 Crore preferential allotment. The capital raise targets non-promoter investors to fund technology transfers.
Novelix Pharmaceuticals has scheduled an EGM for July 01, 2026, via video conferencing. The board fixed June 24, 2026, as the cut-off date for shareholder e-voting eligibility.
Novelix Pharmaceuticals approved a Rs. 6.84 Crore preferential allotment of 12,00,000 equity shares. The capital raise targets non-promoter investors at Rs. 57 per share.
Novelix Pharmaceuticals signed an agreement with Germany's GMBU e.V. for commercial scale-up of Astaxanthin production. This collaboration follows successful pilot-scale production at Hyderabad facilities.
Novelix Pharmaceuticals allotted 9,50,000 equity shares to promoter group entities following warrant conversions. The ₹2.81 Crore equity infusion strengthens the company's capital base.
Novelix Pharmaceuticals allotted new equity shares to its promoter group via a preferential offer. This issuance increases promoter stake through a formal regulatory allotment process.
Novelix Pharmaceuticals promoters converted warrants into 1,50,000 equity shares on May 29, 2026. This conversion increases the total promoter voting shareholding to 2.09%.
Novelix Pharmaceuticals allotted 28,10,000 equity shares upon warrant conversion, receiving ₹4.22 Crore. This increases the company's paid-up equity capital to ₹23.90 Crore.
Novelix Pharmaceuticals reported zero deviation in the utilization of ₹16.25 Crore raised through preferential issues. The Audit Committee reviewed and confirmed the funds were used as intended.